Pre-clinical trials of an intranasal version of the
Pre-clinical [trials] have now been completely concluded. We need to launch clinical [trials]. We wanted to conduct this as one of the stages of the already existing vaccine, skipping a number of stages but this wasn’t approved. And all the trials need to follow the full program – with Phases One, Two and Three of clinical trials. This costs about 400 mln rubles (over $5 mln – TASS),” the developer said.
He added that the intranasal vaccine “is the same Sputnik V, the second component which we spray into the nasal cavity using a special syringe with a special nozzle.”
The researcher expects that the trials will be financed by Moscow authorities since “Moscow has already invested in the trials of a vaccine for children and in a number of projects on monitoring the vaccine’s efficacy against various strains and in other projects,” the newspaper notes.
As reported earlier, the intranasal form of the Sputnik V vaccine against coronavirus will consist of two components. The vaccine helps to develop a local immunity, therefore it will be most likely recommended to those who have contraindications to injections.